Please wait
Illumina, Inc. (ILMN) is listed on NMS in the Healthcare sector, with exposure to Diagnostics & Research. This page brings together the current share price, valuation, dividend context, business summary, and a practical current view so you can assess the stock faster.
Healthcare
₦44.7T
N/A
34.72
Current price
₦291,615.00
Updated Updated 23h ago
Conviction
75/100
Confidence
Low
Market tone
neutral · 75/100
Entry
Medium · 75/100
Recent price action for ILMN, so the page starts with the stock itself before the deeper analysis.
At least one liquidity signal is strong now, though large orders should still be staged.
Valuation view
Looks relatively cheap vs peers
Income view
Income signal not strong yet
Market tone
neutral (75/100) — price action, attention, and recent context all lean here.
Entry view
Medium (75/100) — The company is profitable on the latest reported numbers.
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. The company has a collaboration with Labcorp Holdings Inc. for the development of oncology treatments through applications of sequencing solutions across the healthcare ecosystem; and strategic collaboration with Integrated DNA Technologies to enable a DRAGEN, secondary analysis pipeline for IDT xGena, FFPE and cfDNA next generation sequencing (NGS) library preparation with custom panels, delivering an integrated, end-to-end solution for somatic oncology research. It also has a data partnership with Center for Data-Driven Discovery in Biomedicine to advance research in pediatric cancer and rare disease. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.
Investors usually follow ILMN for its valuation signal, sector position, and upcoming company events. The goal here is not just to show numbers, but to explain what they mean in plain English.
Official filings
0
Financial reports and company disclosures captured by Eye.
Market events
0
Insider, filing, dividend, and price events.
Source records
3
Captured updates we can trace.
Whisone is bullish because fundamentals are solid at 75/100 while there is no strong bear warning from the current data. Whisone has high conviction here. The final read is being balanced by the weighted scores for fundamentals, technicals, insider flow, sentiment, event flow, and liquidity.
Whisone v2 splits the read into weighted parts so the score is not just one hidden number.
Fundamentals
Growth, margins, cash flow, and valuation.
ROE
33.8%
Return on equity
ROA
8.7%
Return on assets
Debt / equity
0.95
Lower is usually safer.
P/B ratio
11.18
Useful for book value support.
85/100
Direction
Range-bound
Main supports
Business quality and balance-sheet strength are supporting the outlook.
Recent price behavior and momentum still support follow-through.
Recent price and fundamentals refreshes improve signal reliability.
What can go wrong
Volatility is elevated, so the path can stay rough even if the thesis is right.
Analyst target data does not currently point to clear upside.
Fair value
₦273,000.00
Analyst view
Buy
Analyst target
₦254,210.52
Forecast refresh
Updated 1d ago
Quality score
73
Growth score
50
These are the external analyst numbers and business outlook figures already synced into the company record.
No external analyst outlook is available for this company yet.
US stock catalog seed
Updated 1d ago
Seeded from the built-in US stock catalog for database discovery and later background refresh.
Price points saved
251
Latest market date
2026-07-23
Illumina, Inc.
Price: ₦291,615.00
P/E: 34.719578
Yield: N/A
ABBV
AbbVie Inc.
Price: ₦389,040.00
P/E: 127.76354
Yield: 2.7%
ABT
Abbott Laboratories
Price: ₦154,590.00
P/E: 33.352753
Yield: 2.5%
ALGN
Align Technology, Inc.
Price: ₦250,522.50
P/E: 28.248322
Yield: 0.0%
Industry
Diagnostics & Research
Employees
8600
Exchange
NMS
Ticker
ILMN
